Home > Cardiology > Early vasodilation in acute HF does not improve outcomes

Early vasodilation in acute HF does not improve outcomes

Conference
ESC 2019
Trial
GALACTIC

Results from the GALACTIC trial showed that early intensive vasodilation does not improve 180-day all-cause mortality and rehospitalisation in patients hospitalised for acute heart failure (HF), despite the use of individualised doses of various agents.

The GALACTIC trial hypothesised that early goal-directed therapy with maximal and persistent vasodilation would be able to achieve better clinical outcomes than standard care given to patients who were hospitalised for acute HF. A total of 781 patients were randomised to early goal-directed therapy or standard care until the moment of discharge. Early goal-directed therapy combined high and personalised doses of vasodilators including sublingual and transdermal nitrates, oral hydralazine for 48 hours to avoid tolerance to nitrates, and rapid up-titration of angiotensin-converting-enzyme inhibitors or angiotensin II receptor blockers. All other therapies including loop diuretic dose and duration, beta-blockers, aldosterone antagonists, and cardiac devices were administered according to current European Society of Cardiology guidelines and at the discretion of the treating physician. Primary endpoint of the trial was a composite of all-cause mortality or rehospitalisation for acute HF at 180 days. Secondary endpoints included quantitative assessment of dyspnoea at days 2 and 6. Participating patients were randomised at a median of 5 hours after presentation. Dyspnoea improved in both groups, and no significant between-group differences were observed. Almost all (99.7%) patients completed the clinical follow-up at 180 days. In total, 30.6%of patients in the early intensive vasodilation group met the primary endpoint versus 27.8%in the standard care group (adjusted HR1.07; 95% CI0.83 to 1.39; P=0.589). Results from predefined subgroup analyses demonstrated consistent results (according to age and left ventricular ejection fraction). Interestingly, a statistically significant interaction of the treatment effect was shown for gender, suggesting that early goal-directed therapy not only fails to benefit women, but it might even be harmful[1].

1. Mueller CE. GALACTIC -Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial. FP Number 3178.ESC Congress 2019, 31 Aug-4 Sept, Paris, France.



Posted on